Limitations of enzyme replacement therapy: current and future.

Area of Science:

• Biotechnology and Pharmaceutical Development
• Rare Disease Therapeutics
• Genetic Medicine

Background:

• Orphan drug legislation (USA 1983, Europe 1999) incentivized development of treatments for rare diseases.
• Lysosomal storage disorders (LSDs) have benefited significantly from these legislative changes.
• Biotechnology firms now pursue treatments for previously unprofitable niche markets.

Purpose of the Study:

• To review the impact of orphan drug legislation on the development of enzyme replacement therapies (ERTs) for LSDs.
• To highlight the successes and limitations of ERTs in treating rare genetic disorders.
• To discuss the future outlook for ERTs in the rare disease landscape.

Main Methods:

• Analysis of the impact of legislative incentives on pharmaceutical R&D for rare diseases.
• Review of clinical and commercial outcomes of approved ERTs for LSDs.
• Examination of ongoing ERT development pipelines for LSDs.

Main Results:

• ERTs, such as for Gaucher disease, demonstrate clinical and financial success, driving further development.
• Approved ERTs target Fabry disease, mucopolysaccharidoses types I and VI, with more in development for types II and Pompe disease.
• Recombinant enzyme production and tissue targeting have improved due to legislative support.

Conclusions:

• Orphan drug laws have successfully fostered ERT development for LSDs, improving patient outcomes.
• Limitations include patient suitability, variable efficacy across organs, and high treatment costs restricting access.
• Continued innovation is expected, but cost and accessibility remain significant challenges for global patient populations.